Atherosclerotic Cardiovascular Disease (ASCVD) is a long-term, progressive condition that leads to the narrowing of arteries due to plaque buildup. It impacts arteries in vital areas, including the heart (coronary arteries), brain (cerebral arteries), and limbs (peripheral arteries). The most prevalent forms of ASCVD include coronary artery disease (CAD), strokes resulting from cerebrovascular complications, and peripheral arterial disease (PAD).

Several risk factors contribute to the development of ASCVD—such as smoking, obesity, sedentary lifestyle, unhealthy eating habits, alcohol use, and genetic predisposition. The disease often remains silent in its early stages but gradually leads to restricted blood flow. As the condition progresses, symptoms may emerge based on the affected arteries, including chest pain (angina), dizziness, fatigue, palpitations, shortness of breath, and cold sweats.

📌 Explore visual trends and statistics:
👉 ASCVD Market Infographic

📊 ASCVD Epidemiological Insights Across the 7MM

The epidemiological framework for ASCVD between 2020 and 2034 in the seven major markets (7MM)—the US, EU4 (Germany, France, Italy, Spain), the UK, and Japan includes:

• Total diagnosed prevalence
  
  

• Gender-wise breakdown
  
  

• Age-based segmentation
  
  

• Comorbidity-related case distribution
  
  

In 2023, there were nearly 55.7 million individuals diagnosed with ASCVD across these markets. The United States led with around 26 million cases, with projections showing continued growth. Among European nations, Germany had the most reported cases (5 million), while France and Spain reported 4 million and 3 million respectively. Japan contributed approximately 8 million diagnosed cases, accounting for 15% of the 7MM total.

In terms of comorbidities, “other coronary heart diseases” (CHD) were the most prevalent, totaling nearly 28 million cases in 2023. Other comorbid conditions included recent acute coronary syndrome (ACS), ischemic stroke, peripheral artery disease (PAD), and chronic kidney disease (CKD).

In the EU4 and the UK, a gender gap was evident—roughly 12 million diagnosed male cases compared to 8 million in females.

📖 For full epidemiological data and forecasts, check the detailed report:
👉 ASCVD Market Analysis Report

💸 ASCVD Market Size and Key Growth Factors

The market size of ASCVD in the 7MM reached an estimated USD 23 billion in 2023. A combination of rising awareness, better screening, and emerging therapies is expected to propel future growth.

Key Market Drivers:

• Established treatment protocols streamline care delivery and enhance therapy adoption.
  
  

• The lack of effective treatments specifically targeting lipoprotein(a) [Lp(a)] opens opportunities for pharmaceutical R&D.
  
  

Market Barriers:

• Patients often struggle with long-term medication adherence and lifestyle modifications, impacting outcomes.
  
  

• Strict regulatory processes can delay the launch of innovative treatments and technologies.
  
  

📊 See how these drivers and barriers shape the landscape:
👉 ASCVD Market Infographic & Trends

🧬 Promising Therapies and Leading Companies in ASCVD

Several novel treatments for ASCVD are under development, aimed at addressing unmet needs and improving outcomes:

• Olpasiran – An RNA-based therapy from Amgen targeting elevated Lp(a) levels
  
  

• Obicetrapib – A promising CETP inhibitor from NewAmsterdam Pharma aimed at lipid modulation
  
  

• Other investigational compounds targeting key atherosclerotic pathways
  
  

Leading companies in the ASCVD drug development landscape include:

• Amgen Inc.
  
  

• Merck Sharp & Dohme Corp.
  
  

• NewAmsterdam Pharma
  
  

📚 Access in-depth pipeline analysis and profiles of top developers:
👉 View ASCVD Companies & Pipeline Drugs